Abstract
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and the association with other autoimmune diseases is well-documented. There are many therapeutic options for the treatment of MS. Most of the available drugs cause drug-induced liver injury (DILI) to variable extents with heterogeneous clinical and biological manifestations, including liver injury with or without signs of hypersensitivity and autoimmunity. The diagnosis of DILI may be particularly difficult because MS is frequently associated with idiopathic autoimmune hepatitis. Recent advances suggest that MS and immune-mediated DILI could be promoted by genetic factors, including HLA genotype. In addition, some of these drugs may promote hepatitis B virus reactivation. This review explores the potential hepatotoxicity of drugs used to treat MS and the criteria to distinguish DILI from idiopathic autoimmune hepatitis associated with MS. The role of susceptible genes both promoting MS and causing the hepatotoxicity of the drug used for MS treatment is also discussed.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference79 articles.
1. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria;Thompson;Lancet Neurol.,2018
2. A Case of Multiple Sclerosis with Atypical Onset Associated with Autoimmune Hepatitis and Silent Coeliac Disease;Franciotta;Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol.,2008
3. Multiple Sclerosis, Interferon Beta and Clinical Thyroid Dysfunction;Kreisler;Acta Neurol. Scand.,2003
4. Rheumatoid Arthritis and Multiple Sclerosis in the Same Patient. Two Case-Reports;Attout;Rev. Rhum. Engl. Ed.,1999
5. Co-Occurrence of Multiple Sclerosis and Myasthenia Gravis in British Columbia;Isbister;Mult. Scler. Houndmills Basingstoke Engl.,2003
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献